Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

AGM Statement

20 Sep 2007 07:01

Angle PLC20 September 2007 For Immediate Release 20 September 2007 ANGLE plc ('ANGLE' or the 'Company') AGM Statement At the Annual General Meeting of ANGLE plc today, Hance Fullerton, retiringChairman, will make the following statement: "ANGLE has made a strong start to the year, continuing to trade in line with theexpectations for the year outlined at our Preliminary Results announcement on 5July. Solid progress has been made in both of our key operating divisions. Our Management services business is now trading profitably and is expected todeliver at least £0.4 million profit for the year. In addition to successfullyimplementing £1m of annualised cost savings, ANGLE has also secured asignificant new contract win with the Innovation Lincolnshire Outreach Programmewhich, as announced on 27 June, will generate £0.9m of revenue for the Companyover a 21 month period. The Group will continue to pursue further such contractsin order to drive revenue growth and broaden its exposure to a pipeline ofpotentially high-value IP opportunities. Solid progress has also been made within our Ventures division. Evidence ofsuccessful value creation has been demonstrated, as announced on 5 July, througha £4 million profit from the gain in fair value of portfolio company Geomerics.Furthermore, in line with our current strategy, operating costs in this divisionhave also been reduced by an estimated £1.3 million on an annualised basis. As previously announced, I am retiring following today's Annual General Meetingand Garth Selvey is succeeding me as non-executive Chairman. I would like tothank the Chief Executive, other directors and senior management for all theirsupport over the years. I look forward to hearing of ANGLE's success in thefuture." Andrew Newland, Chief Executive will add: "I would like to take this opportunity to thank Hance for all his hard work anddedication to ANGLE over the years. Under his stewardship, the Group hasdeveloped from a start-up business to an established leader in IPcommercialisation. We wish Hance all the best for a long and enjoyableretirement and sincerely thank him for his outstanding contribution to ANGLE." Enquiries: ANGLE plc Andrew Newland, Chief Executive 01483 295830Ian Griffiths, Finance Director Collin Stewart Europe Limited 020 7523 8350Mark Connelly Scott Harris 0207 653 0030Stephen Scott, James O'Shaughnessy, Harry Dee Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent
23rd Jul 20147:00 amRNSPreliminary Results
22nd Jul 20147:00 amRNSParsortix Evaluation
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.